PMID- 38198111
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240225
IS  - 2509-4254 (Electronic)
IS  - 2509-4262 (Print)
IS  - 2509-4262 (Linking)
VI  - 8
IP  - 2
DP  - 2024 Mar
TI  - A Systematic Literature Review of Health-Related Quality of Life Outcomes and 
      Associated Utility Values in Relapsed and/or Refractory Large B Cell Lymphoma.
PG  - 171-190
LID - 10.1007/s41669-023-00464-5 [doi]
AB  - BACKGROUND: In this ever-expanding treatment landscape, there is a lack of 
      consolidated health-related quality of life (HRQOL) outcomes and utility reports 
      in relapsed or refractory (R/R) large B cell lymphoma (LBCL) to inform health 
      care policy and decision-maker assessments for both old and new products. These 
      assessments can have a direct effect on what treatment options are available to 
      patients and physicians. OBJECTIVE: A systematic literature review (SLR) was 
      performed to understand the HRQOL evidence for treatments in R/R LBCL and 
      identify associated health utility values. METHODS: The SLR searched and screened 
      literature published from 1 January 2003 to 2 May 2022. Studies were screened 
      based on Population, Intervention, Comparator, Outcome, Study design criteria 
      established a priori and were assessed by two independent reviewers; quality 
      assessments of the evidence were performed in accordance with health technology 
      assessment recommendations from the National Institute for Health and Care 
      Excellence. Several types of therapies were included, such as chimeric antigen 
      receptor (CAR) T cell products (lisocabtagene maraleucel, axicabtagene 
      ciloleucel, tisagenlecleucel), novel therapies (selinexor, nivolumab, polatuzumab 
      vedotin, and bendamustine), salvage therapies, and rituximab. RESULTS: The review 
      identified 33 unique studies reporting HRQOL, including 15 economic studies that 
      reported health state utility values, 9 clinical trials, 7 health technology 
      assessment reports, and 1 each of a vignette-based study and a point-in-time 
      survey. Improvements in general and/or lymphoma-specific HRQOL measures were 
      observed with CAR T cell therapy in both the second-line and third-line or later 
      settings. On-treatment utility values for CAR T cell therapies ranged from 0.50 
      to 0.74. Values for remission/progression-free survival (0.70-0.90) and for 
      disease progression (0.39-0.59) were similar across studies. For novel therapies, 
      utility values were 0.83 for progression-free survival and ranged from 0.39 to 
      0.71 for disease progression. On-treatment utility values for salvage 
      chemotherapy ranged from 0.63 to 0.67. CONCLUSIONS: Overall, the evidence 
      synthesized in this SLR provides a comprehensive understanding of the HRQOL 
      evidence in R/R LBCL. This article identified several sources for utility values 
      in the published literature showing variation in the HRQOL outcomes for patients 
      across a variety of therapeutics. Treatment of R/R LBCL with CAR T cell therapies 
      was associated with improvement in health utility values. Mixed results were 
      found for novel therapies and salvage therapies. More data are needed as new 
      therapies are used in this patient population to inform treatment 
      decision-making.
CI  - (c) 2024. The Author(s).
FAU - Liu, Fei Fei
AU  - Liu FF
AD  - Bristol Myers Squibb, 3401 Princeton Pike, Lawrence Township, Princeton, NJ, 
      08648, USA. feifei.liu@bms.com.
FAU - Bartlett, Meaghan
AU  - Bartlett M
AD  - EVERSANA, Burlington, ON, Canada.
FAU - Craigie, Samantha
AU  - Craigie S
AD  - EVERSANA, Burlington, ON, Canada.
LA  - eng
PT  - Systematic Review
DEP - 20240110
PL  - Switzerland
TA  - Pharmacoecon Open
JT  - PharmacoEconomics - open
JID - 101700780
PMC - PMC10883903
COIS- Fei Fei Liu is an employee of Bristol Myers Squibb and owns stock in the company. 
      Samantha Craigie and Meaghan Bartlett are employees of EVERSANA, which collected 
      consulting fees from Bristol Myers Squibb for their work.
EDAT- 2024/01/10 12:42
MHDA- 2024/01/10 12:43
PMCR- 2024/01/10
CRDT- 2024/01/10 11:28
PHST- 2023/11/30 00:00 [accepted]
PHST- 2024/01/10 12:43 [medline]
PHST- 2024/01/10 12:42 [pubmed]
PHST- 2024/01/10 11:28 [entrez]
PHST- 2024/01/10 00:00 [pmc-release]
AID - 10.1007/s41669-023-00464-5 [pii]
AID - 464 [pii]
AID - 10.1007/s41669-023-00464-5 [doi]
PST - ppublish
SO  - Pharmacoecon Open. 2024 Mar;8(2):171-190. doi: 10.1007/s41669-023-00464-5. Epub 
      2024 Jan 10.